RxDoctor Payments Data

Alexcia James

Nurse Practitioner · Miami Gardens, FLNPI 1003242108

Payments from drug & device makers

$547in general payments, 2019–2025

Across 26 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$138
  • Amgen$117
  • Novo Nordisk$95
  • Amarin Pharma, Inc.$39
  • Abbott$38
  • Johnson & Johnson$33
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$547100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$547 in reported general payments places this provider in the 65th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$188,800
Medicare patients
280
Services billed
1,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban63$60,309
EntrestoSacubitril/Valsartan27$43,616
JardianceEmpagliflozin11$18,955
FarxigaDapagliflozin Propanediol14$13,134
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$7,112
Fluticasone-SalmeterolFluticasone Propion/Salmeterol59$6,513
Albuterol Sulfate HfaAlbuterol Sulfate63$2,333
Bumetanide37$2,175
Metoprolol Succinate148$1,855
Furosemide185$1,157
Wixela InhubFluticasone Propion/Salmeterol12$1,057
Torsemide26$925
Isosorbide Mononitrate ErIsosorbide Mononitrate58$770
Losartan Potassium54$657
Pantoprazole Sodium49$588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$31$43,61627 claims
AstraZenecaFarxiga$13$13,13414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Miami Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →